NEUROCRINE BIOSCIENCES INC
For the period ended Jun 30, 2026. Filed Jul 31, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Jul 31, 2026
NBIX$169.14+0.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| Six Months EndedJune 30, | ||
|---|---|---|
| (in millions) | 2026 | 2025 |
| Cash flows from operating activities: | ||
| Net income | $342.3 | $115.4 |
| Adjustments to reconcile net income to net cash from operating activities: | ||
| Stock-based compensation | 122.2 | 105.6 |
| Depreciation | 15.6 | 12.9 |
| Amortization of inventory fair-value step-up | 3.0 | — |
| Accretion of discount on available-for-sale debt securities, net | (1.6) | (8.0) |
| Realized loss on sale of available-for-sale debt securities | 5.2 | — |
| Amortization of acquired intangible assets | 16.5 | 2.0 |
| Changes in fair values of equity investments | (26.5) | 37.3 |
| Deferred income taxes | (86.4) | (51.1) |
| Non-cash lease expense | 3.6 | 14.3 |
| Gain on sale of business, net of transaction costs | (28.6) | — |
| Other | — | 1.2 |
| Change in operating assets and liabilities: | ||
| Accounts receivable | (165.7) | (116.6) |
| Inventory | (2.2) | 0.4 |
| Accounts payable and accrued liabilities | (22.8) | 12.1 |
| Income tax assets and liabilities | 60.2 | 15.8 |
| Other assets and liabilities, net | 47.4 | 25.5 |
| Cash flows from operating activities | 282.2 | 166.8 |
| Cash flows from investing activities: | ||
| Purchases of available-for-sale debt securities | (856.9) | (588.3) |
| Sales and maturities of available-for-sale debt securities | 2,527.5 | 596.7 |
| Acquisition of business, net of cash acquired | (2,358.5) | — |
| Proceeds from sale of business | 63.2 | — |
| Capital expenditures | (16.9) | (23.2) |
| Cash flows from investing activities | (641.6) | (14.8) |
| Cash flows from financing activities: | ||
| Proceeds from borrowings under revolving credit facility | 600.0 | — |
| Repayments of borrowings under revolving credit facility | (600.0) | — |
| Payment of debt issuance costs | (6.7) | — |
| Issuances of common stock under benefit plans | 108.4 | 46.5 |
| Taxes paid related to net share settlement of equity awards | (58.4) | — |
| Repurchases of common stock | (66.0) | (167.7) |
| Cash flows from financing activities | (22.7) | (121.2) |
| Effect of exchange rate changes on cash and cash equivalents | — | 0.2 |
| Change in cash, cash equivalents and restricted cash | (382.1) | 31.0 |
| Cash, cash equivalents and restricted cash at beginning of period | 721.0 | 241.0 |
| Cash, cash equivalents and restricted cash at end of period | $338.9 | $272.0 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.